- Barely a year after Farmabios, Novasep and PharmaZell unified under a single name, Axplora announces the launch of its Code of Business Conduct, a major step to reinforce its commitment to integrity
- Axplora also seeks to extend its ethical business practices beyond its organization through a Supplier Code of Conduct
A symbol to reinforce Axplora’s commitment to integrity
We are pleased to announce the launch of Axplora’s Code of Business Conduct, available in 4 languages (English, French, German, Italian) in digital format. This foundational document applies to all employees on all sites, from senior management to individual contributor, and provides guidance so that all employees act with integrity and in compliance with applicable rules and regulations.
To make sure that all employees fully align with the described rules and framework, Axplora will be rolling out e-learning sessions on several of the topics covered by the Code of Business Conduct. This learning approach aims to help employees understand and comply with applicable rules on a day-to-day basis.
An additional support tool – the Supplier Code of Conduct – is also launched to ensure our stakeholders and partners align their own practices with our compliance commitments.
Latest news
News
March 17, 2026
Biopharma’s Growing Emphasis on Highly Potent Drugs Drives Axplora Manufacturing Expansion
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in HPAPI capacity help customers bring these complex therapies to market faster $60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy New […]
News
March 17, 2026
Axplora announces multi-million-euro investment to expand lyophilization at Le Mans and appoints François Houbart as Head of Site
Axplora announces multi-million-euro investment to expand lyophilization at Le Mans and appoints François Houbart as Head of Site 18 February, 2026 – Axplora, a global CDMO Partner for complex small molecules and antibody-drug conjugates (ADCs), today announced a multi-million-euro investment to expand lyophilization (freeze-drying) capabilities at its Le Mans, France Site strengthening its ability to deliver […]
Press Release
October 08, 2025
Axplora initiates global investments exceeding €100m in 2025
Raubling, 7 October, 2025 – Axplora, a global leader in small molecule API manufacturing and a trusted partner to the world’s most innovative pharmaceutical companies, today announced that the total investments initiated across its global network in 2025 will exceed €100 million. This commitment underscores Axplora’s determination to accelerate growth, strengthen capabilities, and reinforce its […]
We enable our partners to fully realize their ambitions.
Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.